EVEREST-1: A Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530 an Autologous Logic-gated Tmod Chimeric Antigen Receptor T Cell (CAR T) in Heterozygous HLA-A*02 Adult Subjects with Recurrent Unresectable Locally Advanced or Metastatic Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Brief description of study

This is a study to see if a new treatment called A2B530 is safe and effective for people with certain types of cancer that have not been able to be removed with surgery. The patient must have a specific HLA type known as HLA-A*02. A2B530 is a type of therapy called CAR T cell therapy. It is a form of engineered immune cells derived from a patient and is designed to target cancer cells. The study will be done in two parts. In the first part, a small group of people will receive different amounts of A2B530 in order to decide,what the best dose of the drug will be. In the second part, additional people will get the best dose of A2B530 discovered from part 1 and evaluate how well this dose works amongst a wider group of people.


Clinical Study Identifier: s23-00280
Principal Investigator: Salman Rafi Punekar.
Other Investigators: Nila Theresa De La Rosa, Joshua K Sabari, Samantha VanMaanen, Ahmad S. Al-Homsi, Jessica Wang, Elaine Shum, Nina Beri, Kristen Spencer, Scot Niglio, Keriann M Scavone, Kathleen M Madden, Nancy Chan, Caitlin Elizabeth Ryan, Eneil De La Pena, Douglas K Marks.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.